Table 3 The PK of test and reference preparation about CYP2C19 phenotypes.

From: Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers

CYP2C19 gene polymorphisms

AUC0–t (ng h mL−1)

AUC0–∞

Cmax(ng mL−1)

T1/2 (h)

Tmax (h)

λz (h−1)

CL (L h kg−1)

Vd (L kg−1)

T

R

T

R

T

R

T

R

T

R

T

R

T

R

T

R

EM (N = 12)

552.90 ± 391.42

591.09 ± 401.03

563.59 ± 378.58

600.82 ± 387.43

633.25 ± 295.94

690.50 ± 338.19

0.74 ± 0.19

0.78 ± 0.17

0.25 (0.17, 0.75)

0.25 (0.17, 0.5)

0.99 ± 0.2

0.92 ± 0.19

50.95 ± 28.09

45.23 ± 23.32

35.03 ± 18.45

24.68 ± 11.92

IM (N = 24)

1520.14 ± 1437.90

1475.31 ± 1356.51

1558.7 ± 1495.48

1508.26 ± 1402.83

1044.21 ± 320.07

1060.33 ± 303.17

1.13 ± 0.65

1.11 ± 0.63

0.25 (0.17, 0.5)

0.25 (0.08, 0.5)

0.75 ± 0.27

0.76 ± 0.26

20.4 ± 11.91

21.72 ± 11.78

25.55 ± 9.06

26.78 ± 7.98

PM (N = 4)

4526.56 ± 651.59

4913.02 ± 738.77

4679.13 ± 627.44

5089.02 ± 742.13

1650.00 ± 451.66

1670.00 ± 530.28

2.48 ± 0.24

2.46 ± 0.16

0.3 (0.25 0.5)

0.29 (0.17, 1)

0.28 ± 0.03

0.28 ± 0.18

4.32 ± 0.54

4.28 ± 0.25

15.79 ± 3.32

15.79 ± 0.74

p (EM/IM)

 < 0.05

 < 0.05

 < 0.05

 < 0.05

 < 0.001

0.002

0.049

0.08

0.96

0.67

0.01

0.06

0.04

0.5

 < 0.001

 < 0.001

p (EM/PM)

 < 0.001

 < 0.001

 < 0.001

 < 0.001

 < 0.001

 < 0.001

 < 0.001

 < 0.001

0.48

0.24

 < 0.001

 < 0.001

0.06

0.15

0.005

0.004

p (IM/PM/)

 < 0.001

 < 0.001

 < 0.001

 < 0.001

0.002

0.002

 < 0.001

 < 0.001

0.41

0.14

0.002

0.001

0.045

0.009

0.01

0.007

  1. Cmax maximum blood concentration, Tmax time to maximum blood concentration, AUC0–t Area under curve from time 0 (baseline) to time t, AUC0–∞ Area under curve from zero to infinity, T1/2 elimination half-life, λz apparent end elimination rate constant, CL plasma clearance, Vd, apparent volume of distribution. Data was presented in mean ± standard deviation. p > 0.05, not significant.